UUDA Stock Overview
Operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Syntara Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.042 |
| 52 Week High | AU$0.043 |
| 52 Week Low | AU$0.008 |
| Beta | 0.56 |
| 1 Month Change | 12.00% |
| 3 Month Change | 86.67% |
| 1 Year Change | 278.38% |
| 3 Year Change | -33.33% |
| 5 Year Change | -51.72% |
| Change since IPO | -94.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| UUDA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -0.2% | -0.4% |
| 1Y | 278.4% | -17.1% | 7.9% |
Return vs Industry: UUDA exceeded the German Pharmaceuticals industry which returned -17.1% over the past year.
Return vs Market: UUDA exceeded the German Market which returned 7.9% over the past year.
Price Volatility
| UUDA volatility | |
|---|---|
| UUDA Average Weekly Movement | 18.9% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UUDA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: UUDA's weekly volatility has decreased from 24% to 19% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 21 | Gary Phillips | syntaratx.com.au |
Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company’s lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson’s disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation.
Syntara Limited Fundamentals Summary
| UUDA fundamental statistics | |
|---|---|
| Market cap | €76.22m |
| Earnings (TTM) | -€8.25m |
| Revenue (TTM) | €3.48m |
21.9x
P/S Ratio-9.2x
P/E RatioIs UUDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UUDA income statement (TTM) | |
|---|---|
| Revenue | AU$5.76m |
| Cost of Revenue | AU$8.30m |
| Gross Profit | -AU$2.53m |
| Other Expenses | AU$11.13m |
| Earnings | -AU$13.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0087 |
| Gross Margin | -43.98% |
| Net Profit Margin | -237.09% |
| Debt/Equity Ratio | 0.2% |
How did UUDA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 10:09 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Syntara Limited is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| Anubhav Saxena | Bell Potter |
| Thomas Wakim | Bell Potter |